Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing;Fenotipo heterogéneo del síndrome de QT largo causado por la mutación KCNH2-H562R: importancia del estudio genético familiar

Revista Espanola de Cardiologia

Volumn 68, Issue 10, 2015, Pages 861-868

  Muñoz Esparza, Carmen ^a   García Molina, Esperanza ^a   Salar Alcaraz, Mariela ^a   Peñafiel Verdú, Pablo ^a   Sánchez Muñoz, Juan J ^a   Martínez Sánchez, Juan ^a   Cabañas Perianes, Valentín ^a   Valdés Chávarri, Mariano ^a   García Alberola, Arcadio ^a   Gimeno Blanes, Juan R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

KCNH2 gene; Long QT syndrome; Sudden death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; POTASSIUM CHANNEL HERG; DNA; KCNH2 PROTEIN, HUMAN;

AGED; ARTICLE; CASE REPORT; CLINICAL EVALUATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FAINTNESS; FOLLOW UP; GENE; GENETIC SCREENING; HETEROZYGOTE; HUMAN; KCNH2 GENE; LONG QT SYNDROME; MALE; MISSENSE MUTATION; PHENOTYPE; QT PROLONGATION; QTC INTERVAL; SUDDEN DEATH; SYMPATHECTOMY; TORSADE DES POINTES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PEDIGREE; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; CHILD, PRESCHOOL; DNA; DNA MUTATIONAL ANALYSIS; ELECTROCARDIOGRAPHY; ERG1 POTASSIUM CHANNEL; FEMALE; GENETIC TESTING; HEART CONDUCTION SYSTEM; HETEROZYGOTE; HUMANS; LONG QT SYNDROME; MALE; MUTATION; PEDIGREE; PHENOTYPE; YOUNG ADULT;

EID: 84942366122     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2014.10.022     Document Type: Article

References (33)

1. P.L. Hedley, P. Jorgensen, S. Schlamowitz, R. Wangari, J. Moolman-Smook, P.A. Brink, and et al. The genetic basis of long QT and short QT syndromes: a mutation update Hum Mutat. 30 2009 1486 1511
2. M.C. Sanguinetti HERG1 channelopathies Pflugers Arch. 460 2010 265 276
3. A.J. Moss, W. Zareba, E.S. Kaufman, E. Gartman, D.R. Peterson, J. Benhorin, and et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel Circulation. 105 2002 794 799
4. W. Shimizu, A.J. Moss, A.A. Wilde, J.A. Towbin, M.J. Ackerman, C.T. January, and et al. Genotype-phenotype aspects of type 2 long QT syndrome J Am Coll Cardiol. 54 2009 2052 2062
5. D. Migdalovich, A.J. Moss, C.M. Lopes, J. Costa, G. Ouellet, A. Barsheshet, and et al. Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome Heart Rhythm. 8 2011 1537 1543
6. P.J. Schwartz, A.J. Moss, G.M. Vincent, and R.S. Crampton Diagnostic criteria for the long QT syndrome. An update Circulation. 88 1993 782 784
7. P.M. Rautaharju, B. Surawicz, L.S. Gettes, J.J. Bailey, R. Childers, B.J. Deal, and et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval J Am Coll Cardiol. 53 2009 982 991
8. S.G. Priori, A.A. Wilde, M. Horie, Y. Cho, E.R. Behr, C. Berul, and et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013 Heart Rhythm. 10 2013 1932 1963
9. J.D. Kapplinger, D.J. Tester, B.A. Salisbury, J.L. Carr, C. Harris-Kerr, G.D. Pollevick, and et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test Heart Rhythm. 6 2009 1297 1303
10. D. Sharma, K.A. Glatter, V. Timofeyev, D. Tuteja, Z. Zhang, J. Rodriguez, and et al. Characterization of a KCNQ1/KVLQT1 polymorphism in Asian families with LQT2: implications for genetic testing J Mol Cell Cardiol. 37 2004 79 89
11. L. Monserrat, A. Mazzanti, M. Ortiz-Genga, R. Barriales-Villa, D. Garcia-Giustiniani, and J.R. Gimeno-Blanes The interpretation of genetic tests in inherited cardiovascular diseases Cardiogenetics. 1 2011 30 36
12. C. Andreasen, J.B. Nielsen, L. Refsgaard, A.G. Holst, A.H. Christensen, L. Andreasen, and et al. New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants Eur J Hum Genet. 21 2013 918 928
13. L. Zhang, K.W. Timothy, G.M. Vincent, M.H. Lehmann, J. Fox, L.C. Giuli, and et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes Circulation. 102 2000 2849 2855
14. G. Millat, P. Chevalier, L. Restier-Miron, A. Da Costa, P. Bouvagnet, B. Kugener, and et al. Spectrum of pathogenic mutations and associated polymorphisms in a cohort of 44 unrelated patients with long QT syndrome Clin Genet. 70 2006 214 227
15. J.N. Johnson, and M.J. Ackerman QTc: how long is too long? Br J Sports Med. 43 2009 657 662
16. K. Takenaka, T. Ai, W. Shimizu, A. Kobori, T. Ninomiya, H. Otani, and et al. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome Circulation. 107 2003 838 844
17. I.S. Chattha, R.W. Sy, R. Yee, L.J. Gula, A.C. Skanes, G.J. Klein, and et al. Utility of the recovery electrocardiogram after exercise: a novel indicator for the diagnosis and genotyping of long QT syndrome? Heart Rhythm. 7 2010 906 911
18. J.M. Horner, M.M. Horner, and M.J. Ackerman The diagnostic utility of recovery phase QTc during treadmill exercise stress testing in the evaluation of long QT syndrome Heart Rhythm. 8 2011 1698 1704
19. H.L. Tan, A. Bardai, W. Shimizu, A.J. Moss, E. Schulze-Bahr, T. Noda, and et al. Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications Circulation. 114 2006 2096 2103
20. J.A. Kim, C.M. Lopes, A.J. Moss, S. McNitt, A. Barsheshet, J.L. Robinson, and et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2 Heart Rhythm. 7 2010 1797 1805
21. J.R. Gimeno, M.J. Oliva, J. Lacunza, A.G. Alberola, M. Sabater, J. Martínez-Sánchez, and et al. Características de la muerte súbita en las cardiopatías hereditarias Rev Esp Cardiol. 63 2010 268 276
22. J.N. Johnson, N. Hofman, C.M. Haglund, G.D. Cascino, A.A. Wilde, M.J. Ackerman, and et al. Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy Neurology. 72 2009 224 231
23. A. Guill, A. Tormos, J. Millet, E.J. Roses, A. Cebrián, L. Such-Miquel, and et al. Heterogeneidades inducidas en el interval QT mediante enfriamiento/calentamiento epicárdico local. Estudio experimental Rev Esp Cardiol. 67 2014 993 998
24. CredibleMeds. Composite list of all QT drugs and the List of drugs to avoid for patients with congenital LQTS [actualizado 20 Ago 2013; citado 22 Ago 2013]. Disponible en: http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/
25. M.W. Brandriss, W.S. Richardson, and S.S. Barold Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review Clin Infect Dis. 18 1994 995 998
26. K.L. Lee, M.H. Jim, S.C. Tang, and Y.T. Tai QT prolongation and torsades de pointes associated with clarithromycin Am J Med. 104 1998 395 396
27. H. Ohtani, C. Taninaka, E. Hanada, H. Kotaki, H. Sato, Y. Sawada, and et al. Comparative pharmacodinamicanakysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats Antimicrob Agents Chemother. 44 2000 2630 2637
28. D.P. Zipes, A.J. Camm, M. Borggrefe, A.E. Buxton, B. Chaitman, M. Fromer, and et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation. 114 2006 e385 e484
29. A.J. Moss, W. Zareba, W.J. Hall, P.J. Schwartz, R.S. Crampton, J. Benhorin, and et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome Circulation. 101 2000 616 623
30. S.G. Priori, C. Napolitano, P.J. Schwartz, M. Grillo, R. Bloise, E. Ronchetti, and et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers JAMA. 292 2004 1341 1344
31. J.A. Kim, C.M. Lopes, A.J. Moss, S. McNitt, A. Barsheshet, J.L. Robinson, and et al. Trigger-specific risk factors and response to therapy in type 2 long QT syndrome Heart Rhythm. 7 2010 1797 1805
32. P. Chockalingam, L. Crotti, G. Girardengo, J.N. Johnson, K.M. Harris, J.F. Van der Heijden, and et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol J Am Coll Cardiol. 60 2012 2092 2099
33. P.J. Schwartz, S.G. Priori, M. Cerrone, C. Spazzolini, A. Odero, C. Napolitano, and et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome Circulation. 109 2004 1826 1833